论文部分内容阅读
目的 侵及或侵出浆膜的胃癌腹膜种植转移是术后生存率降低的重要因素之一。本文探讨术后腹腔内化疗对防治腹膜复发的价值。方法 对84例侵及或侵出浆膜又无植及远处转移病人行术后腹腔内化疗(治疗组)其治疗效果与同期未行腹腔内化疗(对照组)进行对比分析。结果 腹腔化疗组无明显毒副反应,术后一年、二年生存率分别为86.7％、71.2％,对照组生存率为70.8％、60.5％。后一年、二年生存率分别为86.7％、71.2％,对照组生存率为70.8％、56.5％。治疗组的一年、二年生存率明显高于对照组(P<0.01)。结论 腹腔内化疗因其腹腔内药物浓度高,剂量大,毒副反应少,对侵及或侵出浆膜的胃癌有着防止复发的重要作用。
Objective To invade or invade the serous membrane of peritoneal carcinoma of the stomach is one of the important factors for the decrease of the postoperative survival rate. This article discusses the value of postoperative intraperitoneal chemotherapy for the prevention and treatment of peritoneal recurrence. Methods The therapeutic effects of intraperitoneal chemotherapy (treatment group) in 84 patients with invasive or invasive serosa and without graft and distant metastasis were compared with those without intraperitoneal chemotherapy (control group) during the same period. Results No significant side effects were observed in the intraperitoneal chemotherapy group. The one-year and two-year survival rates were 86.7% and 71.2%, respectively. The survival rates in the control group were 70.8% and 60.5%. The one-year and two-year survival rates were 86.7% and 71.2%, respectively. The control group survival rates were 70.8% and 56.5%. The one-year and two-year survival rates of the treatment group were significantly higher than those of the control group (P<0.01). Conclusion Intraperitoneal chemotherapy has a high concentration of intraperitoneal drugs, a large dose, and few side effects. It has an important role in the prevention of recurrence of gastric cancer invading or invading the serosa.